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Abstract: Although a large number of compounds have been identified with antiviral activity 
against orthopoxviruses in tissue culture systems, it is highly preferred that these compounds 
have activity in vivo before they can be seriously considered for further development. One of 
the most commonly used animal models for the confirmation of this activity has been the use 
of mice infected with either vaccinia or cowpox viruses. These model systems have the 
advantage that they are relatively inexpensive, readily available and do not require any special 
containment facilities; therefore, relatively large numbers of compounds can be evaluated  
in vivo for their activity. The two antiviral agents that have progressed from preclinical 
studies to human safety trials for the treatment of orthopoxvirus infections are the cidofovir 
analog, CMX001, and an inhibitor of extracellular virus formation, ST-246. These 
compounds are the ones most likely to be used in the event of a bioterror attack. The purpose 
of this communication is to review the advantages and disadvantages of using mice infected 
with vaccinia and cowpox virus as surrogate models for human orthopoxvirus infections and 
to summarize the activity of CMX001 and ST-246 in these model infections. 
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1 Background and Introduction 
Following the tragic events of September 11th and the anthrax mailings in 2001 in the U.S., several 
laboratories strengthened their ongoing efforts in the discipline of biodefense. Of particular concern was 
the possibility of an intentional release of smallpox virus as a bioweapon. Funding from government 
agencies as well as some biotechnology companies was increased and allocated into research and 
development programs targeted towards the discovery of novel or improved compounds that may be 
valuable as therapies against orthopoxvirus infections. While more efficacious vaccines for smallpox 
prevention were also sought and funding provided for that research, the goal of moving at least two new 
therapeutic compounds into Phase I human clinical trials for safety was of utmost priority. The Project 
Bioshield Act of 2004 was a multi-billion dollar appropriation made to stockpile both vaccines and 
therapeutics for use in response to bioterror events. As recently as July 2010, one million doses of 
smallpox vaccine for certain immune-compromised populations were delivered to the national stockpile 
from work funded through Project Bioshield (HHS press release, 7/14/10). Two new antiviral drugs, 
CMX001 and ST-246 are also being considered for inclusion. 
Mice have been used extensively for determination of efficacy of antiviral therapies for orthopoxvirus 
infection and the results have been published as far back as the 1940s [1]. The advantages of using this 
particular small laboratory animal are numerous. The susceptibility of immunocompetant mice to lethal 
or non-lethal infections with vaccinia virus or cowpox virus provides an important model system. Lethal 
models often provide the most definitive and conclusive evidence for antiviral effect. Since laboratory 
mice are readily available, larger group sizes can be utilized to detect even weakly active compounds and 
avoid repetitive testing. Chemists can then use that feedback to synthesize more active analogs. The 
smaller size of the BALB/c weanling mouse in particular, typically less than 15 grams at the initiation of 
most studies using aerosol or intranasal infections, utilizes small quantities of test compound in 
concurrent toxicity and efficacy studies. Often, only 50 to 75 mg of an experimental compound is 
necessary for evaluation. In addition, immunodeficient mice provide models for humans that are 
immunosuppressed, including post-operative solid organ transplant recipients, leukemia or AIDS 
patients. To simulate these conditions, severe combined immunodeficient (SCID), athymic, and 
knock-out mice have been infected with orthopoxviruses and used for antiviral evaluations [2–4].  
The disadvantages of rodent models infected with vaccinia or cowpox viruses include the fact that 
initiation of infection requires a substantial viral inoculum to obtain a lethal infection. This necessity is 
dissimilar to a smallpox bioterror event where inhalation or contact with only a few airborne infectious 
viruses to humans could begin a pandemic event [5]. In addition, the pathology of advanced disease in the 
mouse infected with vaccinia or cowpox virus is not analogous to variola virus related causes of death in 
human patients which generally result in about a 30% mortality rate, even in naïve, unvaccinated persons. 
A fatal encephalitis is one cause of death in human patients either post-vaccinal or following acute 
infection, whereas, the mouse exhibits multi-organ involvement with inflammatory processes and 
significant lung pathology [6,7]. Mice infected with ectromelia virus require lower infectious doses   
of virus for initiation of a lethal infection with a pathology that more closely resembles smallpox in 
humans [8]. A disadvantage of this model is the requirement for more stringent containment procedures 
which may preclude its use for large scale in vivo screening studies. Viruses 2010, 2                            2683 
 
2. Review 
Cidofovir (CDV) has been reported to have very good efficacy against orthopoxvirus infections in a 
number of model systems [3,4,9–11] and has been stockpiled for use in orthopoxvirus infections or 
complications from vaccination under an investigation new drug protocol [12]. However, practical use of 
CDV is limited due to the required intravenous route for administration and its dose-limiting 
nephrotoxicity severely limits its usefulness even in an emergency bioterror or naturally occurring event. 
CMX001, originally known as hexadecyloxypropyl-cidofovir (HDP-CDV), was only one of several 
ether-lipid esters of CDV synthesized in a search for compounds that were orally active and had reduced 
toxicity for use in the treatment of orthopoxvirus and other DNA virus infections [13]. The lipid side 
chains added to CDV enhanced cellular and oral uptake and altered the biodistribution patterns of CDV 
which reduced the known nephrotoxicity associated with intravenously administered CDV 
(Vistide®)  [14–16]. The active metabolite, the acyclic nucleoside phosphonate, inhibits viral DNA 
polymerase independent of viral phosphorylation. A number of nucleoside phosphonates and their 
analogs were evaluated in vitro for their activity against orthopoxviruses and many were significantly 
more potent than CDV [13,17]. Four of the more active and least toxic ether lipid esters of cidofovir were 
subsequently tested in mice for toxicity and efficacy against several different vaccinia virus strains: WR, 
IHD or CDV- resistant -CDV-R [18–20]. Mice infected with cowpox virus, strain BR were also included 
for similar evaluation [18]. 
Since CDV was the first and only drug that has been approved for emergency use under an 
investigational new drug protocol for treatment of an orthopoxvirus infection or adverse vaccine 
reactions, its efficacy was confirmed in our laboratory using mice infected with either vaccinia or cowpox 
virus prior to efficacy testing of the new ether lipid esters of CDV. It was also included as a positive 
control in all experiments used to evaluate the activity of new agents. The in vitro activity of CDV and 
four of the most promising of the ether lipid esters of CDV, hexadecyloxypropyl-CDV (HDP-CDV, 
CMX001), octadecyloxyethel-CDV (ODE-CDV), oleyloxypropyl-CDV (OLP-CDV), and oleyloxyethyl-
CDV (OLE-CDV) against vaccinia virus is shown in Table 1. The four ether lipid esters of cidofovir had 
effective concentrations (EC50 in μM) ranging from 0.8 to 0.06 compared to CDV at 31, a 50-100-fold 
difference. Clearly all four compounds had greater efficacy than CDV [13]. Their selectivity indices (SI) 
ranged from 37 to 933 compared to CDV at >10. 
Table 1. Antiviral activity and cytotoxicity of ether lipid esters of CDV in human foreskin 
fibroblast cells. 
  Vaccinia Virus Copenhagen  Cowpox Virus Brighton 
Compound EC50 (µM)
a  CC50 (µM)
a  SI
b  EC50 (µM)
a  CC50 (µM)
a  SI
b 
CDV  31 ± 5.4  >317 ± 0  >10  42 ± 5.4  >317 ± 0  >7.5 
OLP-CDV  0.4 ± 0.2  87±15  218  0.6 ± 0.3  87±15  145 
OLE-CDV  0.06 ± 0.02  56 ± 29  933  0.07 ± 0.02  56 ± 29  800 
CMX001  0.8 ± 0.4  31 ± 24  37  0.6 ± 0.3
  31 ± 24  53 
ODE-CDV  0.2 ± 0.1  14  65  0.3 ± 0.3  14  49 
Adapted from [18]. a. Values are the mean of 2 or more assays ± standard deviation. b. Selectivity Index 
(SI) = CC50/EC50; CC50 (concentration causing cytotoxic effect on 50% of uninfected confluent cells); 
EC50 (effective concentration that reduced plaque formation by 50%). Viruses 2010, 2                            2684 
 
The activity of CDV was next evaluated in mice infected intranasally with vaccinia or cowpox virus to 
determine the essential number of doses, the timing of the doses and the concentrations necessary for 
improved survival. Since CDV had to be administered i.p. and was already available as an intravenous 
solution for human use, the highest dose of 100 mg/kg down to the lowest diluted dose of 3 mg/kg were 
given on multiple days or as a single dose prior to or following lethal infections. As shown in Table 2, 
even a single dose of CDV administered from five days before viral inoculation to three days 
post-exposure could significantly (P ≤ 0.05) improve survival of BALB/c mice lethally infected with 
vaccinia virus. When SCID mice were inoculated i.p. with vaccinia or cowpox virus and treated   
post-viral infection either daily for seven days or three times weekly for 30 days, there was a significant 
increase in the mean survival time of animals while on drug. However, upon cessation of treatment all 
animals eventually died, indicating that drug therapy in the immunocompromised host failed to clear the 
viral infection. A significant reduction in virus replication was detected in liver, spleen, and kidney, but 
not lung samples [2]. 
Table 2. Effect of single dose CDV on mortality of BALB/c mice inoculated intranasally 
with vaccinia virus-WR. 
Treatment
a 
Mortality 
P-value MDD
b P-value 
Number Percent 
Untreated 15/15  100  ---  9.1  --- 
Placebo     Day +1  14/15  93  ---  8.6  --- 
CDV         
100 mg/kg  Day -5  1/15  7  <0.001  10.0  0.7 
30 mg/kg    Day -5  9/15  60  0.08  9.0  NS 
10 mg/kg    Day -5  8/15  53  <0.05  8.8  NS 
3 mg/kg      Day -5  14/15  93  NS  8.5  NS 
CDV         
100 mg/kg  Day -3  2/15  13  <0.001  8.5  NS 
30 mg/kg    Day -3  7/15  47  0.01  9.1  NS 
10 mg/kg    Day -3  15/15  100  NS  8.4  NS 
CDV         
30 mg/kg    Day -1  0/15  0  <0.001  ---  --- 
10 mg/kg    Day -1  2/15  13  <0.001  12.0  0.01 
3 mg/kg      Day -1  12/15  80  NS  8.6  NS 
CDV         
30 mg/kg    Day +1  0/15  0  <0.001  ---  --- 
10 mg/kg    Day +1  0/15  0  <0.001  ---  --- 
3 mg/kg      Day +1  4/15  27  <0.001  9.0  NS 
CDV         
30 mg/kg    Day +3  1/15  7  <0.001  8.0  NS 
10 mg/kg    Day +3  0/15  0  <0.001  ---  --- 
3 mg/kg      Day +3  8/15  53  <0.05  8.6  NS 
Adapted from [2]. a. Animals were treated one time only for each time period beginning Day -5, -3,  
or -1 or Day +1 or Day +3 after viral inoculation. b. MDD = Mean Day of Death. c. NS = Not 
significant when compared to the placebo control. 
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With the activity of CDV in mice infected with vaccinia and cowpox virus well established in our 
laboratory, the CDV analogs were then evaluated in these murine models. When the four CDV analogs 
were given to uninfected mice to determine toxicity, CMX001 given orally on five consecutive days 
appeared to be the least toxic of the group as measured by mortality [18]. When groups of mice were 
treated with 5 mg/kg for five consecutive days beginning 24, 48 or 72 h post intranasal inoculation with 
an LD90 dose of vaccinia virus-WR, those treated with CMX001, ODE-CDV or OLE-CDV had improved 
survival and the results are summarized in Table 3. Similar to the results obtained earlier in SCID mice, 
animals that were treated with CMX001 or ODE-CDV had titers of virus in their liver, spleen and kidney 
that were reduced by 3 to 7 log10 compared with vehicle-treated mice. Again, no significant reduction of 
virus replication in lung tissue was observed [18]. 
Table 3. Effects of oral treatment with HDP-CDV, ODE-CDV, OLP-CDV or OLE-CDV on 
mortality of BALB/c mice inoculated intranasally with vaccinia virus-WR. 
Treatment and time 
(h) of administration
a 
Mortality 
P value for 
mortality 
MDD
b  P value for 
MDD 
No. of mice that 
died/total no. infected 
% 
Placebo (saline at 24 h)  15/15  100    6.8 ± 0.4   
CDV         
24 0/15  0  <0.001     
48  4/15  27  <0.001  7.8 ± 0.5  0.01 
72 0/15  0  <0.001     
Placebo (water at 24 h)  15/15  100    6.8 ± 0.7   
CMX001         
24  2/15  13  <0.001  11.0 ± 4.2  <0.05 
48  10/15  67  <0.05  8.0 ± 1.2  <0.01 
72  14/15  93  NS  7.4 ± 0.9  0.07 
ODE-CDV         
24 0/15  0  <0.001     
48  6/15  40  0.001  8.0 ± 3.0  0.06 
72 15/15  100  NS
c  7.3 ± 0.8  <0.01 
OLP-CDV         
24  11/15  73  NS  9.6 ± 1.3  <0.001 
48  12/15  80  NS  7.3 ± 1.7  <0.01 
OLE-CDV         
24  4/15  27  <0.001  7.5 ± 3.3  NS 
48  9/15  60  <0.05  7.4 ± 0.7  <0.01 
72  14/14  100  NS  6.5 ± 0.5  NS 
Adapted from [18]. a. The animals were treated with 5 mg/kg of compound once daily for 5 days 
beginning 24, 48 or 72 h after viral inoculation. b. MDD, mean ± standard deviation day of death.  
c. NS, not significant compared to the placebo treated controls. 
 
Other investigators have reported that when given as a single dose 24 h after infection, CMX001 
at 100, 50 or 25 mg/kg improved survival following lethal intranasal infections of mice using a different 
strain of vaccinia virus, strain IHD [19]. These results are summarized in Table 4. While lower doses of 
10 mg/kg or less given over five consecutive days were not effective (Table 4), some toxicity was also Viruses 2010, 2                            2686 
 
documented by decreases in weight gains of uninfected mice that received multiple doses of 
CMX001 [19]. In subsequent studies using a CDV- resistant strain of vaccinia virus, mice that were 
intranasally infected with the non-lethal CDV-resistant vaccinia virus-CDV-R and treated with CMX001 
at 50 mg/kg p.o. on Days 1 and 3 post-inoculation, had significantly lower lung consolidation scores 
(0.5 versus 2.8) and snout virus titers (4.1 versus 5.3) than placebo treated mice [20].  
Table 4. Effects of oral treatment with CMX001 on vaccinia virus IHD respiratory infection in mice. 
Compound 
(mg/kg per day) 
Treatment 
days
a 
Mortality P-value  for 
mortality 
Mean day of 
death
b 
P-value 
for MDD  #dead/#infected Percent 
Placebo  1–5  10/10  100    6.5 ± 0.5   
CDV
c (100)  1  1/10  10  <0.001  17.0 ± 0   
CMX001 (100)  1  0/10  0  <0.001     
(50) 1 0/10  0  <0.001     
(25)  1  2/10  20  <0.001  16.5 ± 0.7  <0.001 
(10)  1–5  7/10  70  NS*  10.9 ± 0.7  <0.001 
(5)  1–5  7/10  70  NS  10.4 ± 2.6  <0.01 
(2.5)  1–5  10/10  100  NS  7.9 ± 0.7  <0.01 
Adapted from [19]. a. Starting 24 h after virus exposure. b. Of mice that died prior to day 21. c. CDV 
was given by ip administration. *NS, not significant when compared to placebo treated controls. 
 
The same four ether lipid esters of cidofovir described above were also evaluated by us using in vitro 
efficacy against cowpox virus strain BR and compared to CDV [18]. Their selectivity indices (SI) ranged 
from 49 to 800 compared to CDV at >7.5. Their effective concentrations (EC50 in μM) ranged from 0.6 
to 0.07 compared to CDV at 42 (Table 1). Indeed all four compounds again had greater activity than 
CDV. Mice treated with a fixed daily oral dose of 6.7 mg/kg for five consecutive days beginning 24, 48 
or 72 h post inoculation with cowpox virus had improved survival rates with CMX001, ODE-CDV, 
OLP-CDV and OLE-CDV as summarized in Table 5.  
In summary, orally administered CMX001 was the most effective analog of CDV tested, and   
proved highly effective in mouse models of orthopoxvirus infections. It was generally as effective   
as CDV given parenterally. 
While CMX001 was an intentional design conceptualized to improve upon the already known antiviral 
properties of CDV, ST-246 was a uniquely synthesized analogue based on optimization of an active 
compound detected during large scale, high throughput screening efforts [21]. The effective 
concentration (EC50 in μM) of ST-246 was 0.01 against vaccinia virus -NYCBH and 0.05 against cowpox 
virus-BR. In these studies, ST-246 had greater efficacy than CDV and inhibited CPE formation more 
robustly than CDV in cell culture [21]. When evaluated in vitro against vaccinia-COP, vaccinia-WR or 
cowpox-BR viruses in our laboratory, ST-246 also had greater activity than CDV, but had about 
equivalent potency with CMX001. ST-246 had higher selectivity indices against each virus strain than 
did CDV or CMX001 due to its reduced toxicity compared with the nucleotides (Table 6). Its mechanism 
of action is unlike CDV or CMX001 and was reported to affect the extracellular egress of formed viral 
particles which diminishes viral spread from cell to cell or, as in animal models, into a systemic 
disease [22].  Viruses 2010, 2                            2687 
 
Table 5. Effects of oral treatment with CMX001, ODE-CDV, OLP-CDV or OLE-CDV on 
mortality of BALB/c mice inoculated intranasally with cowpox virus-BR. 
Treatment and time 
(h) of administration
a 
Mortality  P value for 
mortality 
MDD
b  P value 
for MDD No. of mice that 
died/total no. infected 
% 
Placebo (saline at 24 h)  15/15  100    9.7 ± 0.6   
CDV          
48 0/15  0  <0.001     
72  5/15  33  <0.001  13.2 ± 3.0  <0.01 
Placebo (water at 24 h)  15/15  100    9.3 ± 0.6   
CMX001          
24  6/15  40  0.001  9.5 ± 4.8  NS
c 
48  12/14  86  NS  10.5 ± 3.7  NS 
72  7/15  47  <0.01  12.7 ± 3.3  <0.001 
ODE-CDV          
24  3/13  23  <0.001  9.3 ± 6.1  NS 
48  6/14  43  <0.01  12.7 ± 4.9  0.01 
72  7/13  54  0.02  11.6 ± 4.1  0.07 
OLP-CDV          
24  12/14  86  NS  11.4 ± 2.5  <0.01 
48  4/14  29  <0.001  12.5 ± 3.7  0.09 
72  12/14  86  NS  10.3 ± 2.1  0.02 
OLE-CDV          
24  8/15  53  <0.01  13.0 ± 6.2  NS 
48  5/15  33  <0.001  12.0 ± 3.4  <0.001 
72  11/14  79  NS  11.5 ± 4.5  0.02 
Adapted from [18]. a. The animals were treated with 6.7 mg/kg of compound once daily for 5 days 
beginning 24, 48 or 72 h after viral inoculation. b. MDD, mean ± standard deviation day of death.  
c. NS, not significant compared to the placebo treated controls. 
 
When ST-246 was given orally to mice at 50 mg/kg twice daily for 14 days following a lethal 
intranasal infection of vaccinia virus, 100% survival was achieved [21]. Using an alternative model, 
where mice were injected intravenously using vaccinia virus, ST-246 given orally at 50 or 15 mg/kg 
twice daily for five days resulted in a dose dependent reduction in tail lesion formation by day 8 
post-inoculation [21]. Studies performed in our laboratory evaluated various dosing regimens for efficacy 
in mice against either vaccinia or cowpox virus [23]. Either longer durations or delays in beginning 
treatment were required for efficacy of ST-246 against cowpox virus infection in mice, predictably so 
with the longer term to mortality in the lethal intranasal cowpox virus model of 8–9 days versus six days 
for vaccinia virus as shown in Table 7. Higher doses of 100 mg/kg given orally once daily were generally 
more effective against mortality from cowpox virus than lower doses when there were delays of treatment 
initiation of 48 to 72 h (Table 8). When ST-246 was evaluated in immunocompromised animals, it 
significantly prolonged survival [3], but did not alter mortality indicating that this drug, in the absence of 
a functional immune system, is also unable to clear virus infection. One important observation regarding 
ST-246 was a lack of toxicity among various species of animals even when high doses were administered 
for relatively long periods of time. Viruses 2010, 2                            2688 
 
Table 6. Cytotoxicity and antiviral activity of ST-246 or CMX001 against vaccinia or 
cowpox virus in human foreskin fibroblast cells. 
  Vaccinia Virus Copenhagen  Vaccinia Virus WR  Cowpox Virus Brighton 
Compound CC50 (µM)
a  EC50 (µM)
a  SI
b  EC50 (µM)
a   SI
b  EC50 (µM)
a  SI
b 
ST-246  >100 ± 0  0.05 ± 0.02  >2000  0.1 ± 0.05  >1000  0.48 ± 0.01  >208 
CMX001  42 ± 25  0.14 ± 0.09  300  0.13 ± 0.01  323  0.24 ± 0.1  175 
CDV  >317 ± 0  29.2 ± 14  >10.9  33 ± 13  >9.6  41.1 ± 4.2  >7.7 
Adapted from [24]. a. Values are the mean of 2 or more assays ± standard deviation. b. Selectivity 
Index (SI) = CC50/EC50; CC50 (concentration causing cytotoxic effect on 50% of uninfected confluent 
cells); EC50 (effective concentration that reduced plaque formation by 50%). 
 
Several factors led to our decision to initiate synergy studies with CMX001 and ST-246. First, there 
was proven efficacy of both CMX001 and ST-246 in small animal models of orthopoxvirus infections. 
Second, both compounds have been tested in large animal trials using monkeypox or smallpox models. 
Third, the mechanism of action for each compound was distinctly different and not expected to result in 
combined toxicities in vivo. The benefits of combined therapies would be the ability to use reduced 
dosages of each compound, reduce the likelihood of the development of resistance and overcome 
intentionally engineered viruses that had resistance factors for nefarious intent. Additionally, the high 
level resistance attained with a single point mutation for ST-246 makes the drug highly vulnerable to the 
development of resistance, but its use in combination requires virus to become resistant to both drugs and 
effectively raises the genetic barrier of both ST-246 and CMX001. 
In vitro combination studies using CMX001 and ST-246 were performed against both vaccinia and 
cowpox virus [24]. While strong synergistic activity was found against vaccinia virus with very low 
doses across a broad range of combinations, higher concentrations of ST-246 were required for producing 
similar synergy with cowpox virus (Figure 1). A series of animal studies using combinations of CMX001 
with or without ST-246 in cowpox virus-infected mice showed less than anticipated synergy in vivo but 
this may have been due to small numbers of animals and variability in animal to animal pathogenesis of 
infection. There were modest, but improved, survival rates at suboptimal combination levels when 
compared to treatment with single agent alone (Table 9) [24]. Five of the groups of mice treated with 
combinations of CMX001 with ST-246 had reduced mortality (P ≤ 0.01) or increases in mean day to 
death (P ≤ 0.01) compared to vehicle treated groups when treatments were initiated six days post cowpox 
virus inoculation.  
Both of these antiviral agents have successfully completed human Phase I clinical trials and have been 
given to a limited number of vaccinia virus-infected patients or in the case of CMX001, other dsDNA 
virus infected patients under the FDA compassionate use policy with anecdotal successes.  
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Table 7. Effect of duration of treatment with ST-246 on mortality of BALB/c mice inoculated intranasally with cowpox or vaccinia virus. 
  Cowpox Virus, strain BR  Vaccinia Virus, strain WR 
Treatment
a 
Mortality 
P-Value MDD
b P-Value 
Mortality 
P-Value MDD
b P-Value 
Number Percent  Number  Percent 
5 day duration + 4 h                   
Vehicle 15/15  100  ---  9.1  ---  15/15  100  ---  6.1  --- 
ST-246 100 mg/kg  13/15  87  NS  11.6  0.001 2/15  13  <0.001  3.0  <0.05 
5 day duration + 24h                   
Vehicle 15/15  100  ---  8.6  ---  15/15  100  ---  6.3  --- 
ST-246 100 mg/kg  11/15  73  NS  12.4  <0.001 1/15  7  <0.001 3.0 0.08 
CDV 15 mg/kg  0/15  0  <0.001  ---  ---  1/15  7  <0.001  15.0  0.08 
7 day duration + 4 h                   
Vehicle 15/15  100  ---  8.2  ---  15/15  100  ---  5.7  --- 
ST-246 100 mg/kg  1/15  7  <0.001  5.0 0.08  3/15  20  <0.001  6.3 NS 
7 day duration + 24 h                   
Vehicle 15/15  100  ---  8.5  ---  15/15  100  ---  6.3  --- 
ST-246 100 mg/kg  6/15  40  0.001  9.3  NS 1/15  7  <0.001  11.0  0.09 
10 day duration + 4 h                   
Vehicle 15/15  100  ---  8.3  ---  15/15  100  ---  6.1  --- 
ST-246 100 mg/kg  4/15  27  <0.001  8.0 NS  5/15  33  <0.001  10.6  0.06 
10 day duration + 24 h                   
Vehicle 15/15  100  ---  7.9  ---  15/15  100  ---  6.1  --- 
ST-246 100 mg/kg  6/15  40  0.001  13.2  <0.01  0/15  0  <0.001  ---  --- 
14 day duration + 4 h                   
Vehicle 14/15  93  ---  9.1  ---  15/15  100  ---  5.6  --- 
ST-246 100 mg/kg  1/15  7  <0.001  3.0  0.09 3/15  20  <0.001  5.3  0.05 
14 day duration + 24 h                   
Vehicle 15/15  100  ---  8.5  ---  15/15  100  ---  6.7  --- 
ST-246 100 mg/kg  0/15  0  <0.001  ---  ---  1/15  7  <0.001  3.0  0.09 
Adapted from [23]. a. Mice were treated with durations ranging from 5 to 10 days with treatment beginning from 4 to 24 h post viral inoculation.   
b. MDD = Mean Day of Death. c. NS = Not significant when compared to the appropriate vehicle control. Viruses 2010, 2                            2690 
 
Table 8. Effect of dose and delayed treatment with ST-246 on mortality of BALB/c mice 
inoculated intranasally with cowpox virus. 
Treatment
a 
Mortality 
P-Value MDD
b P-Value 
Number Percent 
4 h post inoculation         
Vehicle 15/15  100  ---  9.0  --- 
CDV 15 mg/kg  0/15  0  <0.001  ---  --- 
ST-246   100 mg/kg  1/9  11  <0.001  10.0  NS 
 30  mg/kg  5/10  50  0.01  10.2  NS 
 10  mg/kg  11/12  92  NS  12.2  <0.01 
24 h post inoculation         
Vehicle 15/15  100  ---  8.3  --- 
CDV 15 mg/kg  0/15  0  <0.001  ---  --- 
ST-246 100  mg/kg  4/15  27  <0.001  8.0  NS 
 30  mg/kg  6/15  40  0.001  10.5  NS 
10 mg/kg  11/15  73  NS  14.3  <0.001 
48 h post inoculation         
Vehicle 15/15  100  ---  8.6  --- 
CDV 15 mg/kg  0/15  0  <0.001  ---  --- 
ST-246 100  mg/kg  1/15  7  <0.001  17.0  0.08 
 30  mg/kg  3/15  20  <0.001  14.3  NS 
10 mg/kg  2/15  13  <0.001  11.0  NS 
72 h post inoculation         
Vehicle 15/15  100  ---  8.6  --- 
CDV 15 mg/kg  0/15  0  <0.001  ---  --- 
ST-246 100  mg/kg  6/15  40  0.001  16.8  <0.05 
 30  mg/kg  6/15  40  0.001  12.2  <0.05 
 10  mg/kg  7/15  47  <0.01  13.9  0.001 
Adapted from [23]. a. Animals were treated once daily for 14 days beginning 4, 24, 48 or 72 h post 
viral inoculation. b. MDD = Mean Day of Death. c. NS = Not significant when compared to the 
appropriate vehicle control. 
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Figure 1. Synergistic interactions of CMX001 and ST-246 against vaccinia and cowpox virus 
in vitro. Effect of combinations of CMX001 and ST-246 against vaccinia virus and cowpox 
virus. Inhibition of vaccinia virus replication was evaluated in a CellTiter-Glo® assay with a 
matrix of drug concentrations and an isobologram depicts EC50 values at each drug 
combination (A). A synergy plot is also shown that represents greater than expected inhibition 
with increasing synergistic intensity represented by maroon, yellow and green regions, 
respectively (B). This analysis determined that combinations of ST-246 and CMX001 were 
strongly synergistic with volumes of 326 μM
2% at the 95% confidence level. Efficacy of this 
drug combination was also determined against cowpox virus in a neutral red assay and the 
EC50  isobologram is shown (C). A synergy plot also identified several combinations 
of  concentrations where synergistic interactions occurred and are shown at the 65% 
confidence level (D). This analysis calculated the volume of synergy at 106 μM
2% at the 95% 
confidence level. Excerpted from [24]. 
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Table 9. Effect of combination treatment with ST-246 and CMX001 on mortality of BALB/c 
mice inoculated intranasally with cowpox virus. 
Treatment
a 
Mortality 
P-value MDD
b P-value 
Number Percent 
Vehicle  Day 6  15/15  100  ---  10.9 ± 0.6  --- 
CDV  Day 6          
25 mg/kg   12/15  80  NS  11.5 ± 3.5  NS 
15 mg/kg  9/15  60  0.01  12.8 ± 4.1  NS 
5 mg/kg  14/15  93  NS  11.2 ± 3.2  NS 
ST-246  Day 6           
10 mg/kg   15/15  100  NS  13.5 ± 2.0  0.001 
3 mg/kg   12/15  80  NS  13.5 ± 2.4  0.001 
1 mg/kg   15/15  100  NS  9.5 ± 0.5  <0.001 
CMX001  Day 6          
3 mg/kg  15/15  100  NS  9.9 ± 0.9  0.001 
1 mg/kg  15/15  100  NS  9.9 ± 1.2  0.001 
0.3 mg/kg  15/15  100  NS  10.0 ± 0.8  <0.01 
ST-246 + CMX001  Day 6          
ST-246 10 mg/kg + CMX001 3 mg/kg  1/15  7  <0.001  11.0 ± 0  NS 
ST-246 10 mg/kg + CMX001 1 mg/kg  12/15  80  NS  13.3 ± 3.7  NS 
ST-246 10 mg/kg + CMX001 0.3 mg/kg  15/15  100  NS  11.3 ± 1.6  NS 
          
ST-246 3 mg/kg + CMX001 3 mg/kg  12/15  80  NS  12.4 ± 3.9  NS 
ST-246 3 mg/kg + CMX001 1 mg/kg  9/15  60  0.01  11.7 ± 2.1  NS 
ST-246 3 mg/kg + CMX001 0.3 mg/kg  15/15  100  NS  12.4 ± 1.8  <0.01 
          
ST-246 1 mg/kg + CMX001 3 mg/kg  6/15  40  <0.001  11.8 ± 1.5  NS 
ST-246 1 mg/kg + CMX001 1 mg/kg  15/15  100  NS  9.9 ± 1.0  <0.01 
ST-246 1 mg/kg + CMX001 0.3 mg/kg  14/15  93  NS  10.5 ± 1.3  NS 
Adapted from [24]. a. Animals were treated daily for five days beginning 6 days after   
viral inoculation. b. MDD = Mean Day of Death. c. NS = Not significant when compared to the 
vehicle control. 
 
3. Conclusions 
Mice infected with vaccinia or cowpox viruses have been used to evaluate the efficacy of new antiviral 
agents for their activity against orthopoxvirus infections in order to minimize the quantities of test 
compounds required in efficacy testing while providing predictive data for larger species. Inoculations 
using vaccinia or cowpox virus have utilized the routes of cutaneous, intraperitoneal, intravenous, 
intranasal and inhalational infection. Mice used in these evaluations have generally been 
immunocompetant, however, chemically or genetically immunocompromised mice have also been used. 
There have been several comprehensive reviews in the literature of a variety of antiviral agents tested 
over the past decade against the orthopoxviruses and their outcomes in vitro and in vivo [25–27]. That is 
beyond the scope of this limited review, but numerous publications of peer reviewed research using mice 
infected with vaccinia or cowpox viruses have been illuminating for the purposes of development of new Viruses 2010, 2                            2693 
 
and more potent antivirals with differing mechanisms of action. Mice have proven to be a prudent and 
useful tool in antiviral efficacy testing and, most likely, the only financially feasible tool for evaluating 
combination therapies in vivo.  
Both antiviral drugs, ST-246 and CMX001, were initially evaluated in mice and proved efficacious 
and relatively non-toxic at effective levels. Both have progressed into studies using larger animals, 
including primates infected with monkeypox or variola virus, and have been evaluated for safety in 
humans through Phase I clinical trials. In addition, both compounds have been given to a limited number 
of human patients under the FDA’s approval for compassionate use when adverse events followed 
smallpox vaccinations. Since it is not feasible to conduct large scale Phase III clinical studies for 
orthopoxvirus infections, neither CMX001 nor ST-246 can be approved for use in treatment of smallpox 
or monkeypox infections by conventional means. ST-246 has activity only against poxvirus infections 
and would have to satisfy the requirements of the FDA’s “Animal Rule” to achieve approval. Typically, 
the FDA requires that efficacy of new compounds be established in both a small animal and large animal 
model system prior to being considered for human use. In contrast, CMX001 has excellent activity 
against herpes simplex virus, cytomegalovirus, adenovirus and other DNA viruses; therefore, approval 
for this drug could be obtained through the conduct of clinical trials against one of these other viruses.  
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